onychomycosis
Conditions
Interventions
None listed
Sponsors
Muroran City General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Among patients aged 65 years or older who visited our dermatology outpatient clinic from November 2018 to March 2021, those who were diagnosed with onychomycosis by KOH-based direct microscopy and requested oral treatment were included in the study. Fosravuconazole was administered orally (100 mg/day) for an initial 12 weeks. One hundred and twenty-five patients judged to have responded to the treatment at 48 weeks after completion of the treatment were followed up for subsequent 144 weeks. Patients who experienced a recurrence at less than 24 weeks during the follow-up period were assigned to the short-term recurrence group, and those who experienced a recurrence at 24 weeks or later were assigned to the long-term recurrence group. Fosravuconazole was re-administered and the efficacy was evaluated in each group.
Exclusion criteria
Exclusion criteria: Patients with hepatic impairment (AST or ALT: 2.5 times the upper reference limit or 100 U/L) and patients having been treated with warfarin were excluded from this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1)Patient characteristics: Sex, age, and presence or absence of diabetes/renal failure (on dialysis treatment)/use of immunosuppressive drugs. | — |
Countries
Japan
Contacts
Public ContactAYAKA OKUBO
Muroran City General Hospital Department of Dermatology
Outcome results
None listed